Mirati Therapeutics has completed the public offering of 4,985,706 shares at $202 per paper. Under the SPO, the company sold 4,585,706 shares and 400,000 shares were sold by the company's shareholder. The underwriters sold 625,309 shares of the company itself and 25,000 shares of the company's shareholder as part of a call option exercise. As a result of the SPO, the company raised $926.3 million.